Summary & Overview
HCPCS Level II J7624: Betamethasone Inhalation Solution, DME Unit Dose
HCPCS Level II code J7624 designates a compounded betamethasone inhalation solution provided in unit dose form and billed per milligram for administration through durable medical equipment. This code is relevant nationally for clinicians, DME suppliers, and payers managing inhaled corticosteroid therapies supplied outside traditional pharmacy vial formats. It matters because compounded inhalation products involve specialized preparation, dosing precision, and coordination between compounders and DME providers.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code covers, typical sites of service, and the clinical context for inhaled corticosteroid therapy delivered via DME. The publication outlines billing and service-line considerations, common modifier usage where available, and high-level benchmark topics such as utilization patterns and coverage implications. Data not available in the input is explicitly noted where applicable.
This summary provides the foundational information clinicians, billing professionals, and policy analysts need to understand where J7624 fits in billing workflows and payer coverage frameworks for compounded inhalation medications.
Billing Code Overview
HCPCS Level II code J7624 represents betamethasone inhalation solution, compounded product, administered through durable medical equipment (DME), unit dose form, billed per milligram. This code describes a compounded corticosteroid formulation prepared for inhalation and supplied for use with home or clinic respiratory DME devices.
-
Service type: Compounded inhalation medication administration via DME
-
Typical site of service: Home health or outpatient settings where durable medical equipment for inhalation therapy is used
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or adult with moderate to severe asthma or other corticosteroid-responsive chronic obstructive airway disease requiring inhaled corticosteroid therapy when prefilled commercial preparations are unavailable or when a custom concentration is needed. The patient presents to a hospital outpatient infusion center, ambulatory surgery center, or home health setting where inhalation therapy is delivered via durable medical equipment (DME) such as a nebulizer. A clinician (pulmonologist, allergist/immunologist, or respiratory therapist) documents the indication, orders a compounded betamethasone inhalation solution in unit dose form with the required concentration per milligram, and specifies administration via the patient’s DME. A pharmacist compounds and dispenses the unit-dose vials, labels them with concentration and mg per unit, and the respiratory therapist or home health nurse administers or supervises administration through the nebulizer. Clinical workflow includes medication order entry, compounding verification, DME compatibility check, patient education on nebulizer use, monitoring for response and adverse effects (eg, oral candidiasis, hoarseness, systemic steroid effects), and documentation of dose, lot number, and route. Billing uses HCPCS Level II code J7624 reported per milligram for the compounded betamethasone solution, with applicable modifiers to indicate service circumstances (for example, modifier AS for ambulatory surgery center facility, or modifier QX when using a specific modifier pair for advanced practitioners). Typical sites of service are hospital outpatient departments, ambulatory surgery centers, long-term acute care facilities, and patient homes under home health services when DME is used.